PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758217
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758217
Global Endovascular Abdominal Aortic Aneurysm (AAA) Market to Reach US$3.8 Billion by 2030
The global market for Endovascular Abdominal Aortic Aneurysm (AAA) estimated at US$3.0 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Stent Graft, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Synthetic Fabric Graft segment is estimated at 2.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$806.9 Million While China is Forecast to Grow at 7.6% CAGR
The Endovascular Abdominal Aortic Aneurysm (AAA) market in the U.S. is estimated at US$806.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$773.8 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.
Global Endovascular Abdominal Aortic Aneurysm (AAA) Market - Key Trends & Drivers Summarized
What Technological Shifts Are Redefining the Treatment Landscape for AAA?
The management of abdominal aortic aneurysms (AAA) has seen a paradigm shift from open surgical repair to minimally invasive techniques, primarily led by endovascular aneurysm repair (EVAR). Technological advancements in stent graft design, catheter delivery systems, and imaging guidance have enabled EVAR to become the dominant intervention method in many high-income healthcare systems. The core of EVAR technology lies in modular stent grafts that can be introduced via femoral artery access and deployed precisely at the aneurysm site, effectively excluding the weakened vessel wall from systemic circulation. The shift toward percutaneous, suture-less access and low-profile devices has significantly expanded the treatable patient population, including those with higher surgical risk.
Next-generation EVAR systems are emphasizing anatomical adaptability and long-term sealing performance. The development of fenestrated and branched endografts has allowed surgeons to treat aneurysms that were once considered unsuitable for conventional EVAR due to short or angulated necks, or involvement of visceral branches. Innovations such as polymer-based sealing rings, repositionable grafts, and integrated imaging markers are addressing common complications like endoleaks, migration, and access issues. Additionally, the emergence of intraoperative imaging systems, including 3D fusion imaging and robotic-assisted navigation, is streamlining procedural accuracy and reducing contrast and radiation exposure. These technological strides are not only optimizing procedural outcomes but also influencing treatment guidelines and surgeon preferences globally.
Which Patient Demographics and Risk Profiles Are Driving Clinical Demand?
The burden of abdominal aortic aneurysms is rising, largely influenced by the aging global population and prevalence of modifiable risk factors such as smoking, hypertension, and hyperlipidemia. AAAs are most commonly diagnosed in men aged 65 and older, though incidence among older women is increasingly recognized in epidemiological studies. As a result, screening programs have been introduced in several developed countries targeting at-risk populations, particularly male smokers over the age of 65. The broader implementation of ultrasound-based screening has led to earlier detection of asymptomatic aneurysms, thus expanding the pool of patients eligible for elective EVAR procedures before rupture occurs.
In high-risk surgical populations-such as the elderly or those with comorbidities like chronic obstructive pulmonary disease (COPD), renal dysfunction, or coronary artery disease-EVAR offers a viable treatment alternative to traditional open repair. This has driven demand across tertiary hospitals, ambulatory surgical centers, and even hybrid operating rooms tailored for vascular interventions. Furthermore, the growing number of patients requiring reintervention after initial EVAR due to graft degeneration or aneurysm sac enlargement is creating a secondary demand channel for newer, more durable graft technologies. The inclusion of women in AAA risk stratification protocols and the detection of aneurysms through incidental imaging are also contributing to procedural growth, though anatomical differences still pose challenges for universal device applicability.
How Are Regional Ecosystems and Market Access Influencing Uptake?
North America and Western Europe remain the most mature markets for EVAR, driven by high procedural volumes, advanced hospital infrastructure, and favorable reimbursement policies. The U.S. has been a leading adopter of EVAR, supported by the presence of major medical device manufacturers, continuous clinical trials, and a skilled vascular surgery workforce. In the European context, countries like Germany, the UK, and the Netherlands demonstrate strong procedural integration within public health systems, with EVAR accounting for over 70% of elective AAA repairs. Government-funded screening initiatives in these regions further fuel patient identification and referral for endovascular treatment.
Asia-Pacific is emerging as a key growth frontier, particularly in Japan, China, and South Korea, where the aging population and urbanization are increasing the incidence of vascular diseases. Japan has been at the forefront in terms of technological adoption, with robust procedural experience and widespread use of custom fenestrated devices. In China, expanding healthcare infrastructure and the development of domestic device manufacturers are enabling rapid market expansion. However, reimbursement disparities and training limitations remain challenges in many emerging economies. In Latin America and parts of the Middle East, adoption is slower but growing, especially in private hospitals catering to higher-income patient segments. Market access strategies such as device leasing, surgical training programs, and hybrid OR installation support are proving effective in these underpenetrated regions.
What Are the Key Forces Powering the Growth of the EVAR Market?
The growth in the endovascular abdominal aortic aneurysm (AAA) market is driven by several factors that collectively shape technology development, procedural adoption, and patient access worldwide. Chief among them is the increasing global prevalence of AAAs, a trend exacerbated by demographic aging, lifestyle-related risk factors, and expanded screening practices. As asymptomatic aneurysms are increasingly detected at an earlier stage, elective EVAR is being prioritized as a safer, less invasive alternative to open surgery. This shift is underpinned by continued innovation in stent graft systems that offer enhanced conformability, sealing capacity, and durability, even in anatomically complex cases.
Regulatory pathways and payer structures are also accelerating growth. With FDA approvals for next-gen devices and CE marks expanding to cover advanced fenestrated and branched solutions, clinical adoption is rising in both traditional and niche anatomical segments. The movement toward value-based healthcare models is aligning well with EVAR's lower complication rates, shorter hospital stays, and reduced postoperative morbidity. Hospitals and surgical centers are investing in hybrid ORs and integrated imaging systems to support these procedures, indicating confidence in the long-term utility of endovascular approaches.
Additionally, industry players are increasingly focused on training and education, launching simulation-based programs and global surgeon networks to standardize procedural expertise. The combination of telehealth for follow-up care and wearable devices for postoperative surveillance is further enriching the treatment ecosystem. Meanwhile, increasing investments in R&D-especially into bioresorbable graft components and AI-enabled imaging tools-suggest that EVAR technology is still in a phase of active evolution. These multifactorial drivers point toward sustained expansion in both procedure volumes and device innovation, firmly establishing EVAR as the dominant modality in AAA management for the foreseeable future.
SCOPE OF STUDY:
The report analyzes the Endovascular Abdominal Aortic Aneurysm (AAA) market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product Type (Stent Graft, Synthetic Fabric Graft); End-Use (Hospital End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 41 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.